Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
Amgen Myasthenia Gravis Drug Meets Primary Goal in Phase 3 Trial
Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.
Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...
Medpage Today on MSN6d
Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia Gravis
Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed. The anti-CD19 ...
The Pharma Letter6d
Amgen to file for Uplizna approval in gMG
US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon ...